

Roflumilast (Daxas[®]) – neue Add-on-Therapie für COPD-Patienten mit anhaltenden Exazerbationen

Roflumilast (Daxas[®]) –nouvel adjuvant pour les patients avec BPCO souffrant de constantes exacerbations

Literatur / Références

- 1 Global Initiative for Chronic Obstructive Lung Disease GOLD: Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease, Updated 2013.
http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf , Stand Juni 2013.
- 2 Rabe KF, Update on roflumilast a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease, British Journal of Pharmacology 2011;163:53-67.
- 3 Barnes PJ. Corticosteroids. In: Asthma and COPD. Basic mechanisms and clinical management. Eds. PJ Barnes, J Drazen, S Rennard, N Thomson. Elsevier Science 2009:639-53.
- 4 Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-88.
- 5 Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008;134:1278-86.
- 6 Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers b the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-87.
- 7 Raabe KF, Bateman ED, O'Donnell D et al. Roflumilast an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005;366:563-71.
- 8 Calverley PM, Sanchez-Toril F, McIvor A et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease, Am J Respir Crit Care med 2007;176:154-61.
- 9 Rennard SI, Calverley PM, Goehring UM et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast the importance of defining different subsets of patients with COPD. Resir Res 2011;12(18).DOI:10.1186/1465-9921-12-18.
- 10 Calverley PM, Rabe KF, Goehring UM et al. Roflumilast in symptomatic chronic obstructive pulmonary disease two randomized clinical trials. Lancet 2009;374:685-94.
- 11 Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators tow randomized clinical trials. Lancet 2009;374:695-703.
- 12 Bateman ED, Rabe KF, Calverley PM et al. Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011;38:553-60.DOI:10.1183/09031936.00178710.
- 13 Wedzicha JA, Klaus F, Rabe KF, Martinez FJ et al. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest 2013;143(5):1302-11.
- 14 Russi EW, Karrer W, Brutsche M. et al. Diagnosis and management of chronic obstructive pulmonary disease the Swiss guidelines. Respiration 2013;85:160-174.
- 15 Calverley PM, Martinez FJ, Fabbri LM et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J COPD 2012;7:375–82.
- 16 Wouters EFM, Bredenbröcker D, Teichmann P. et al. Effect of the phosphodiesterase 4 Inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrin Metab 2013;doi:10.1210/jc.2011-2886.
- 17 WhiteWB, Cooke GE, Kowey PR et al. Cardiovascular safety in patients receiving roflumilast for the treatment of chornic obstructive pulmonary disease, CHEST 2013;doi:10.1378/chest.12-2332.
- 18 Bundesamt für Gesundheit BAG, <http://bag.e-mediat.net/SL2007.Web.External/Default.aspx?webgrab=ignore> Stand Juni 2006.
- 19 Samyshkin Y, Schlunegger M, Haefliger S et al. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Internat J of COPD 2013;8:79-87.